XML 388 R25.htm IDEA: XBRL DOCUMENT v3.24.3
Insider Trading Arrangements
 3 Months Ended 12 Months Ended
Sep. 30, 2024
shares
Sep. 30, 2024
shares
Trading Arrangements, by Individual    
Material Terms of Trading Arrangement  
During the fiscal quarter ended September 30, 2024, the following directors and officers (as defined in Exchange Act Rule 16a-1(f)) adopted certain trading plans intended to satisfy Rule 10b5-1(c):
NameTitleAdoption or Termination DatePlan Start DatePlan End Date
Shares Vesting and Subject to Sell-To-Cover (1)
Other Shares Being Sold (Subject to Certain Conditions)
Adeoye OlukotunBoard Member09/24/202412/24/202406/24/2025n/a5,465
Christopher AnzalonePresident and Chief Executive Officer08/16/202403/03/202512/31/2025n/a351,726
Christopher AnzalonePresident and Chief Executive Officer08/22/202412/04/202412/31/20262,082,892n/a
Christopher AnzalonePresident and Chief Executive Officer09/16/202401/02/202512/31/202696,566n/a
Douglass GivenBoard Member09/12/202412/16/202412/31/2024n/a5,547
James HamiltonChief of Discovery and Translational Medicine08/19/202412/04/202411/28/2025n/a30,000
(1) This column indicates the total number of shares vesting, but the 10b5-1 Plan provides for the sale of only those shares necessary to satisfy payment of applicable withholding taxes.
Non-Rule 10b5-1 Arrangement Adopted false  
Rule 10b5-1 Arrangement Terminated false  
Non-Rule 10b5-1 Arrangement Terminated false  
Adeoye Olukotun [Member]    
Trading Arrangements, by Individual    
Name Adeoye Olukotun  
Title Board Member  
Rule 10b5-1 Arrangement Adopted true  
Adoption Date 09/24/2024  
Expiration Date 06/24/2025  
Arrangement Duration 182 days  
Aggregate Available 5,465 5,465
Douglass Given [Member]    
Trading Arrangements, by Individual    
Name Douglass Given  
Title Board Member  
Rule 10b5-1 Arrangement Adopted true  
Adoption Date 09/12/2024  
Expiration Date 12/31/2024  
Arrangement Duration 15 days  
Aggregate Available 5,547 5,547
James Hamilton [Member]    
Trading Arrangements, by Individual    
Name James Hamilton  
Title Chief of Discovery and Translational Medicine  
Rule 10b5-1 Arrangement Adopted true  
Adoption Date 08/19/2024  
Expiration Date 11/28/2025  
Arrangement Duration 359 days  
Aggregate Available 30,000 30,000
Christopher Anzalone August 16 2024 Plan [Member] | Christopher Anzalone [Member]    
Trading Arrangements, by Individual    
Name Christopher Anzalone  
Title President and Chief Executive Officer  
Rule 10b5-1 Arrangement Adopted true  
Adoption Date 08/16/2024  
Expiration Date 12/31/2025  
Arrangement Duration 303 days  
Aggregate Available 351,726 351,726
Christopher Anzalone August 22 2024 Plan [Member] | Christopher Anzalone [Member]    
Trading Arrangements, by Individual    
Name Christopher Anzalone  
Title President and Chief Executive Officer  
Rule 10b5-1 Arrangement Adopted true  
Adoption Date 08/22/2024  
Expiration Date 12/31/2026  
Arrangement Duration 757 days  
Aggregate Available 2,082,892 2,082,892
Christopher Anzalone September 2024 Plan [Member] | Christopher Anzalone [Member]    
Trading Arrangements, by Individual    
Name Christopher Anzalone  
Title President and Chief Executive Officer  
Rule 10b5-1 Arrangement Adopted true  
Adoption Date 09/16/2024  
Expiration Date 12/31/2026  
Arrangement Duration 728 days  
Aggregate Available 96,566 96,566